Hologram QSAR models of 4-[(Diethylamino)methyl]-phenol inhibitors of acetyl/butyrylcholinesterase enzymes as potential anti-alzheimer agents

Molecules

Volumn 17, Issue 8, 2012, Pages 9529-9539

  De Souza, Simone Decembrino ^a   De Souza, Alessandra Mendonça Teles ^a   De Sousa, Ana Carolina Corrêa ^a   Sodero, Ana Carolina Rennó ^a   Cabral, Lúcio Mendes ^a   Albuquerque, Magaly Girão ^b   Castro, Helena Carla ^c   Rodrigues, Carlos Rangel ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Institute of Chemistry   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Acetylcholinesterase; Alzheimer's disease (AD); Butyrylcholinesterase; HQSAR

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PHENOL;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; HOLOGRAPHY; HUMAN; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HOLOGRAPHY; HUMANS; MODELS, MOLECULAR; PHENOL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865469891     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17089529     Document Type: Article

References (27)

1. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: Clinical trials and drug development. Lancet Neurol. 2010, 9, 702-716.
2. Wimo, A.; Winblad, B.; Jönsson, L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010, 6, 98-103.
3. Winblad, B.; Fioravanti, M.; Dolezal, T.; Logina, I.; Milanov, I.G.; Popescu, D.C.; Solomon, A. Therapeutic Use of Nicergoline. Clin. Drug Investig. 2008, 28, 533-552.
4. Benedikz, E.; Kloskowska, E.; Winblad, B. The rat as an animal model of Alzheimer's disease. J. Cell. Mol. Med. 2009, 13, 1034-1042.
5. Robichaud, A.J. Approaches to Palliative Therapies for Alzheimers Disease. Curr. Top. Med. Chem. 2006, 6, 553-568.
6. Gualtieri, F.; Dei, S.; Manetti, D.; Novella Romanelli, M.; Scapecchi, S.; Teodori, E. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. Farmaco Prat. 1995, 50, 489-503.
7. Schliebs, R.; Arendt, T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural. Transm. 2006, 113, 1625-1644.
8. Scarpini, E.; Schelterns, P.; Feldman, H. Treatment of Alzheimer's disease; current status and new perspectives. Lancet Neurol. 2003, 2, 539-547.
9. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66, 137-147.
10. Giacobini, E. Cholinesterase inhibitors: New roles and therapeutic alternatives. Pharmacol. Res. 2004, 50, 433-440.
11. Heritage, T.W.; Lowis, D.R. Molecular Hologram QSAR. In Rational Drug Design: Novel Methodology and Practical Applications; Parrill, A.L., Reddy, M.R., Eds.; American Chemical Society: Washington, DC, USA, 1999; Volume 719, Chapter 14, pp. 212-225.
12. Myint, K.Z.; Xie, X.-Q. Recent Advances in Fragment-Based QSAR and Multi-Dimensional QSAR Methods. Int. J. Mol. Sci. 2010, 11, 3846-3866.
13. Liu, P.; Long, W. Current Mathematical Methods Used in QSAR/QSPR Studies. Int. J. Mol. Sci. 2009, 10, 1978-1998.
14. Castilho, M.S.; Postigo, M.P.; de Paula, C.B.V.; Montanari, C.A.; Oliva, G.; Andricopulo, A.D. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors. Bioorg. Med. Chem. 2006, 14, 516-527.
15. HQSARTM; Tripos: St. Louis, MO, USA, 2010.
16. Yu, L.; Cao, R.; Yi, W.; Yan, Q.; Chen, Z.; Ma, L.; Peng, W.; Song, H. Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorg. Med. Chem. Lett. 2010, 20, 3254-3258.
17. Rodrigues, C.R.; Flaherty, T.M.; Springer, C.; McKerrow, J.H.; Cohen, F.E. CoMFA and HQSAR of acylhydrazide cruzain inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1537-1541.
18. Freitas, R.F.; Oprea, T.I.; Montanari, C.A. 2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L. Bioorg. Med. Chem. Lett. 2008, 16, 838-853.
19. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1998, 110, 5959-5967.
20. Jaiswal, D.; Karthikeyan, C.; Trivedi, P. Rationalization of Physicochemical Properties of Alkanoic Acid Derivatives towards Histone Deacetylase Inhibition. Internet Electron. J. Mol. Des. 2006, 5, 13-26.
21. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M.V.; et al. Pyrano[3,2-c]quinoline-6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds. J. Med. Chem. 2009, 52, 5365-5379.
22. Tang, H.; Wei, Y.-B.; Zhang, C.; Ning, F.-X.; Qiao, W.; Huang, S.-L.; Ma, L.; Huang, Z.-S.; Gu, L.-Q. Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase. Eur. J. Med. Chem. 2009, 44, 2523-2532.
23. Nascimento, É.C.M.; Martins, J.B.L.; dos Santos, M.L.; Gargano, R. Theoretical study of classical acetylcholinesterase inhibitors. Chem. Phys. Lett. 2008, 458, 285-289.
24. Gupta, S.; Fallarero, A.; Järvinen, P.; Karlsson, D.; Johnson, M.S.; Vuorela, P.M.; Mohan, C.G. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques. Bioorg. Med. Chem. Lett. 2011, 21, 1105-1112.
25. SPARTAN'10; Wavefunction, Inc.: Irvine, CA, USA, 2011.
26. SYBYL 8.0; Tripos International: St. Louis, MO, USA, 2010.
27. Doddareddy, M.R.; Lee, Y.J.; Cho, Y.S.; Choi, K.I.; Koh, H.Y.; Pae, A.N. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists. Bioorg. Med. Chem. 2004, 12, 3815-3824.